Suven initiates MAD studies in phase 1 clinical trial for investigational compound SUVN-G3031 Usha Sharma Apr 13, 2015 SUVN-G3031 is a potent, selective, brain penetrant and orally active Histamine H3 inverse agonist being developed for the…
